We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Physiological Left Atrial Staging as a Predictor of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy

MedXY Editorial Team•Sep 15, 2026•Cardiology
risk stratificationHypertrophic CardiomyopathyLeft atrial stagingatrial fibrillation

Highlight

This multicenter retrospective study introduces a novel physiological left atrial (LA) staging system based on hemodynamic pressure and contractile strain in hypertrophic cardiomyopathy (HCM). The LA stages correlate in a graded manner with risk of new-onset atrial fibrillation (NOAF), offering incremental predictive value beyond established models. Longitudinal echocardiography reveals predominantly progressive LA dysfunction, supporting the model’s mechanistic insight into atrial remodeling before AF onset.

Study Background

Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disorder characterized by left ventricular hypertrophy, often accompanied by diastolic dysfunction due to impaired relaxation and elevated filling pressures. Atrial fibrillation (AF) is a common and clinically significant complication in HCM, markedly increasing stroke risk, heart failure, and mortality. Despite guideline recommendations advocating for rigorous AF surveillance, reliable risk stratification for new-onset AF remains an unmet clinical need. Traditional risk models, such as CHARGE-AF and HCM-AF, provide predictive frameworks but lack specificity and mechanistic insight, especially regarding the left atrium’s evolving functional and hemodynamic status preceding AF development.

Study Design

This retrospective multicenter cohort study analyzed consecutive patients with HCM and preserved left ventricular systolic function enrolled between January 2007 and February 2024 at two academic referral centers. Exclusion criteria included prior atrial fibrillation and significant valvular heart disease to isolate the effect of atrial remodeling in HCM. The primary endpoint was new-onset atrial fibrillation (NOAF) during follow-up.

The authors developed a novel LA staging system combining two echocardiographic parameters: the presence of elevated left atrial pressure (reflecting hemodynamic load), and left atrial contractile strain (a sensitive marker of intrinsic atrial myocardial function). The resulting stages were defined as follows:

  • Stage 1: Normal LA pressure and contractile function
  • Stage 2: Elevated LA contractile strain relative to pressure (compensatory augmentation)
  • Stage 3: Elevated LA pressure with loss of contractile augmentation (early dysfunction)
  • Stage 4: Elevated LA pressure with decreased LA contractile strain (advanced dysfunction)
  • Isolated LA contractile dysfunction without elevated pressure

Patients were followed longitudinally with clinical assessments and echocardiography. The staging system’s predictive performance was externally validated in an independent cohort. Landmark, competing risk, and serial echocardiographic analyses assessed robustness and progression of LA remodeling.

Key Findings

Among 705 eligible HCM patients (mean age 57.6±13.0 years, 30.1% female), 101 developed NOAF over a median follow-up of 7.5 years. Risk of NOAF increased stepwise with higher LA stage (adjusted hazard ratio [HR]: 1.83 per stage increment; 95% confidence interval [CI]: 1.42-2.37; P<0.001), independent of confounders.

The LA staging system improved risk prediction beyond established models such as CHARGE-AF and HCM-AF, as demonstrated by net reclassification and discrimination analyses. Landmark analyses at 1 year and competing risk models accounting for death supported the prognostic validity of the LA stages.

External validation in a separate cohort of 425 patients (mean age 59.7±13.5 years, 33.9% female) confirmed consistent prognostic associations. In a subgroup of 217 patients with follow-up echocardiography 4-6 years after baseline, 39.6% remained stable, whereas 43.8% progressed to higher LA stages or developed AF, underscoring a unidirectional evolution of atrial remodeling.

Mechanistically, these findings suggest an adaptive to maladaptive transition of the left atrium in response to progressively impaired ventricular relaxation and elevated diastolic pressure in HCM, which culminates in atrial myopathy and arrhythmogenesis.

Expert Commentary

This study provides a novel and elegant physiological framework integrating hemodynamics and intrinsic myocardial function of the left atrium to characterize atrial remodeling in HCM. Prior risk models focus largely on clinical and electrocardiographic variables, whereas this approach leverages cutting-edge echocardiographic strain imaging, which more sensitively detects early atrial dysfunction.

The unidirectional progression described aligns with current mechanistic understanding of AF pathogenesis—initial compensatory atrial contraction gives way to fibrosis, dilation, and electrical instability, particularly under chronic pressure overload. Clinicians may apply this staging system to enhance individualized risk stratification and prioritize patients for intensified AF monitoring or preventive strategies such as aggressive risk factor modification.

Limitations inherent in retrospective design and referral-center sampling may affect generalizability. Additionally, while the proposed staging represents a physiologic spectrum, specific threshold values and automated quantification methods will need validation in prospective studies across diverse populations.

Conclusion

The physiological left atrial staging system proposed in this study advances understanding of atrial remodeling in hypertrophic cardiomyopathy by combining hemodynamic pressure and intrinsic contractile strain. This novel framework stratifies the risk of new-onset atrial fibrillation with high predictive accuracy and mechanistic insight, potentially enabling more precise AF surveillance strategies and personalized care pathways in HCM.

Future prospective, multicenter trials should confirm these findings and explore whether early interventions targeting atrial function might alter the natural history of LA remodeling and AF incidence in this high-risk group.

Funding and Trial Registration

The study does not specify funding sources or clinical trial registration numbers in the provided abstract. Further details may be obtained from the full journal article.

References

  1. Lim J, Hwang IC, Kim J, et al. Physiological Left Atrial Staging and the Risk of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2026 Aug 27; PMID: 42714359.
  2. Singh A, Desai R, Aronow WS. Atrial fibrillation in hypertrophic cardiomyopathy: pathophysiology and management. J Geriatr Cardiol. 2016;13(4):255-264.
  3. Rohatgi A, Desai MY, Shizukuda Y. Role of left atrial strain in predicting atrial fibrillation: Insights from echocardiographic studies. J Am Soc Echocardiogr. 2020;33(2):179-191.
  4. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: An evolving clinical paradigm. J Am Coll Cardiol. 2012;59(13):1511-1525.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unveiling a Cryptic MYBPC3 Variant Amplifying Missplicing in Hypertrophic CardiomyopathyA deep-intronic MYBPC3 variant magnifies natural mRNA missplicing events, causing hypertrophic cardiomyopathy and explaining previously genotype-negative cases through an ancient founder effect and novel splice regulation.Sep 18, 2026Stratifying Risk for Further Retinal Intervention After Laser Retinopexy: The Impact of Cumulative Clinical FactorsA novel, cumulative risk factor approach identifies patients at increased risk for additional retinal intervention after laser retinopexy for retinal tears, improving surveillance and management strategies.Sep 15, 2026Genotype-Dependent Risk and Impact of Atrial Fibrillation in Dilated Cardiomyopathy: Insights from the SHaRe RegistryThis study reveals genotype-specific differences in atrial fibrillation (AF) risk among dilated cardiomyopathy (DCM) patients, highlighting LMNA mutations as a major predictor of incident AF and its association with worse clinical outcomes,Sep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing &amp; care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody Positivity
Assessment of β-cell dysfunction using stimulated glucose and C-peptide measures improves risk stratification for type 1 diabetes progression among single autoantibody-positive relatives, enabling personalized monitoring and targeted interv
Sep 15, 2026
Global Trends in the Burden of Ischemic Stroke Attributable to Diabetes Versus Atrial FibrillationThis study analyzes global trends comparing ischemic stroke burdens linked to diabetes and atrial fibrillation, revealing a rising impact of diabetes-related stroke and highlighting the need for targeted interventions.Sep 12, 2026
Continuous Glucose Monitoring Using the FreeStyle Libre Pro iQ in Presymptomatic Type 1 Diabetes: Advancements in Early Detection and Risk StratificationThis review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications forSep 12, 2026